Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PALI
stocks logo

PALI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.023
-96.62%
--
--
-0.040
-91.49%
--
--
-0.070
-87.93%
Estimates Revision
The market is revising No Change the revenue expectations for Palisade Bio, Inc. (PALI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 187.31%.
EPS Estimates for FY2025
Revise Downward
down Image
-65.11%
In Past 3 Month
Stock Price
Go Up
up Image
+187.31%
In Past 3 Month
Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.800
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 1.800
sliders
Low
8.00
Averages
8.00
High
8.00
Maxim
Maxim
Buy
maintain
$2 -> $8
2025-11-11
Reason
Maxim
Maxim
Price Target
$2 -> $8
2025-11-11
maintain
Buy
Reason
Maxim raised the firm's price target on Palisade Bio to $8 from $2 and keeps a Buy rating on the shares, citing lower risk as the firm contends that the company's recent financing supports trials for '2108 and potential approval.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Palisade Bio Inc (PALI.O) is -7.72, compared to its 5-year average forward P/E of -1.25. For a more detailed relative valuation and DCF analysis to assess Palisade Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.25
Current PE
-7.72
Overvalued PE
0.34
Undervalued PE
-2.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.61
Current PS
0.00
Overvalued PS
30.61
Undervalued PS
-13.39
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PALI News & Events

Events Timeline

(ET)
2025-12-02
09:00:00
Palisade Bio Appoints James Izanec as VP of Clinical Development
select
2025-10-28 (ET)
2025-10-28
08:49:26
Palisade Bio names Sharon Skare as global leader of clinical operations
select
2025-10-20 (ET)
2025-10-20
08:45:56
Palisade Bio reports initial patient dosing in Phase 1b trial of PALI-2108
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28Benzinga
Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 50 points on Friday.

  • Tilray Brands Inc: Shares of Tilray Brands Inc fell 15% in pre-market trading after announcing a one-for-10 reverse stock split, set to take effect on December 1.

  • Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Inventiva ADR (-7.4%), Anglogold Ashanti PLC (-5.5%), and Lexicon Pharmaceuticals Inc (-5%).

  • Market Movements: SuperX AI Technology Ltd saw a significant drop of 3.9% after a previous surge, while Gold Fields Ltd and Abacus Global Management Inc also reported declines following recent gains.

[object Object]
Preview
5.0
11-21CNBC
Hyundai unveils new rugged concept SUV to highlight off-road aspirations

  • Hyundai's New Concept SUV: Hyundai has unveiled the "Crater" concept SUV at the LA Auto Show, designed to enhance off-road capabilities while incorporating rugged features reminiscent of American SUVs like the Jeep Wrangler and Ford Bronco.

  • Design Philosophy: The Crater concept reflects Hyundai's vision of adventure and exploration, aiming to inspire customers to embrace outdoor experiences, although the company has not confirmed plans for production.

  • Market Strategy: The automaker is focusing on expanding its U.S. vehicle lineup, with a notable increase in sales, achieving a 21.5% growth from 2019 to 2024, and is on track for its fifth consecutive year of record retail sales.

  • Future Directions: Hyundai's commitment to developing versatile and emotionally engaging vehicles is evident in the Crater concept, which aims to meet the evolving demands of U.S. customers for rugged and capable vehicles.

[object Object]
Preview
5.0
10-28Newsfilter
Palisade Bio Names Sharon Skare as Vice President and Global Head of Clinical Operations

  • Leadership Appointment: Palisade Bio has appointed Sharon Skare, PhD(c), as Vice President and Global Head of Clinical Operations, bringing over 24 years of experience in clinical development, particularly in autoimmune and gastrointestinal diseases.

  • Focus on PALI-2108: The company is advancing PALI-2108, a targeted oral therapy for ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 IND submission planned for the first half of 2026.

  • Clinical Development Strategy: PALI-2108 is designed for local delivery to the lower intestine, aiming to maximize therapeutic effects while minimizing systemic side effects, and has shown positive data in recent Phase 1 studies.

  • Company Vision: Palisade Bio aims to transform treatment for autoimmune and fibrotic diseases through innovative therapeutics, emphasizing the need for new therapies that balance efficacy and tolerability.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Palisade Bio Inc (PALI) stock price today?

The current price of PALI is 1.8 USD — it has increased 6.51 % in the last trading day.

arrow icon

What is Palisade Bio Inc (PALI)'s business?

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

arrow icon

What is the price predicton of PALI Stock?

Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Palisade Bio Inc (PALI)'s revenue for the last quarter?

Palisade Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Palisade Bio Inc (PALI)'s earnings per share (EPS) for the last quarter?

Palisade Bio Inc. EPS for the last quarter amounts to -0.38 USD, decreased -83.62 % YoY.

arrow icon

What changes have occurred in the market's expectations for Palisade Bio Inc (PALI)'s fundamentals?

The market is revising No Change the revenue expectations for Palisade Bio, Inc. (PALI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 187.31%.
arrow icon

How many employees does Palisade Bio Inc (PALI). have?

Palisade Bio Inc (PALI) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Palisade Bio Inc (PALI) market cap?

Today PALI has the market capitalization of 268.21M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free